

## Finwire Interview: CEO Anders Weilandt on Chordate Medical's Q1 Report

**Today, May 24, Chordate's CEO Anders Weilandt presented the company's Q1 report for 2024 on Finwire TV. He also answered questions from viewers and talked, among other things, about the reception of Ozilia in industrial and investor circles.**

"Based on the results delivered by PM007, they can see, sometimes with quite a bit of surprise, how effective this is. We can show that we are as good as or better in terms of medical efficacy, we have as good or better response than all other alternatives, and we have no side effect profile to speak of. Then you can see that this must be taken seriously, especially since many people know that many patients prefer to avoid their heavy medications."

"Industry evaluators see that this is extremely exciting, that's the impression we have. This also applies to the clinical side, where many doctors and clinics want to have other options in their toolbox to offer patients when they run out of alternatives. So, the reception is very positive, I would say."

Watch the full interview: [https://www.youtube.com/live/sPwIWGr6fm8?si=ir1\\_dJ1gK\\_uBP1L](https://www.youtube.com/live/sPwIWGr6fm8?si=ir1_dJ1gK_uBP1L)

**For more information, please contact:**

Anders Weilandt, CEO

[anders.weilandt@chordate.com](mailto:anders.weilandt@chordate.com)

Cell: +46 733-874277

**About Chordate**

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH).

Read more at [www.chordate.com](http://www.chordate.com)

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

*N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.*

Press Release  
24 May 2024 14:30:00 CEST

**CHORDATE**  
MEDICAL

---

**Attachments**

[Finwire Interview: CEO Anders Weilandt on Chordate Medical's Q1 Report](#)